Exchange: NASDAQ·Updated 07:30 PM EDT

MGNX News

News
all
press releases
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
Zacks
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
Zacks
More News
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
Zacks
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of +32.50% and -25.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates
Sanara MedTech (SMTI) delivered earnings and revenue surprises of +150.00% and -4.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.
Zacks
Broad-Based MedSurg Growth Likely to Aid MDT's Q4 Performance
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
Zacks
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -1.75% and +12.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Wall Street’s Risk-On Frenzy Returns
Among the session’s standout movers were Quantum Computing, which blasted through more than $1 billion in trading volume after reporting massive revenue growth and expanding its quantum-photonics footprint. Meanwhile, speculative traders also rotated heavily into AI-linked names including Dreamland Limited and media turnaround story BuzzFeed, both of which are holding onto substantial gains throughout the session. $TGNT, $QUBT, $BZFD, $TDIC, $HTCO, $MGNX, $CNCK, $VSTS
24-7 Market News

Advertisement|Remove ads.